Pompano Beach, FL, Dec. 11, 2017 (GLOBE NEWSWIRE) -- BioStem Technologies, Inc. (OTC PINK: BSEM) (“BSEM” or “Company”), in collaboration with the University of Miami’s Department of Dermatology and Cutaneous Surgery Wound Healing Research Laboratory, has launched a study to examine the effects of the Company’s “BSEM17-115” proprietary compound on the healing of third degree burn wounds. The 21-day study is being conducted under the Company’s research and development subsidiary, Blue Tech Industries, Inc. (“Blue Tech”). In the study, third degree burn wounds will be created in a well established porcine model. The wounds will then be immediately treated with the BSEM17-115 compound, sterile gauze and sterile water, and covered with polyurethane film dressing for two days, followed by 5 additional days of 2-hour per day, saturated gauze treatment. The specimens will be histologically evaluated in a “blinded” fashion via light microscopy by a dermatopathologist and examined for: (a) the percent of the wound that has regrown epithelial tissue, (b) the thickness of the regrown epithelium, (c) the amount of inflammatory cell infiltrate, and (d) the amount of new connective tissue and microscopic blood vessels (granulation tissue). Digital photographs will be taken of representative wounds at each assessment in order to document any signs of erythema, infection or wound closure.
The study is part of BioStem Technologies’ R&D effort to develop a pipeline of innovative, new technologies and pharmaceutical drugs that will add to BSEM’s existing product portfolio. “We’re hopeful that this study will demonstrate real effectiveness for this exciting new compound, so that we can begin its productization and commercialization in the very near future,” said Henry Van Vurst, the Company’s CEO. The final report from the University of Miami will include tabulation of the results and data interpretation. If the study produces positive results, the Company is likely to expand into a full study.
About BioStem Technologies, Inc. (OTC PINK: BSEM): BioStem Technologies, Inc. is a global life sciences corporation, providing innovative technologies with a concentration in Pharmaceuticals and Regenerative Medicine. The Company’s mission is to discover, develop and produce the most effective Pharmaceutical and Regenerative Medicine products in the world. The Company is comprised of a diverse group of scientists, physicians, and entrepreneurs who collaborate to create innovative products. These technologies improve the Quality of Life for our patients and, as a result, drive shareholder value.
Forward-Looking Statements: Except for statements of historical fact, the matters discussed in this press release are forward looking and made pursuant to the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "future," "plan" or "planned," "expects," believe" or "projected." These forward-looking statements reflect numerous assumptions and involve a variety of risks and uncertainties, many of which are beyond the company's control that may cause actual results to differ materially from stated expectations. These risk factors include, among others, limited operating history, difficulty in developing, exploiting and protecting proprietary technologies, intense competition and additional risks factors as discussed in reports filed by the company with OTC Markets.